Real-World Data Study Supports Decipher Prostate Genomic Classifier

May 1, 2023

Research analyzing real-world data from over 100,000 patients shows that Veracyte’s Decipher Prostate Genomic Classifier can provide accurate metastatic risk stratification in prostate cancer. Results from the first of two studies to be presented at this year’s American Urological Association meeting compared test results to adverse pathology (AP) found when radical prostatectomy (RP) is performed, which is associated with poorer outcomes.

According to Veracyte, “Results show that Decipher Prostate testing – regardless of individual patients’ test scores – was independently associated with a two-fold increase in conservative management utilization among those with favorable-risk disease (OR 2.1, 95% CI 1.9-2.5, p<0.001). Additionally, higher Decipher Prostate scores were associated with RP, upgrading, upstaging and AP, whereas greater tumor volume was only significantly associated with receipt of RP.”

To read more, click here.